Active Biotech Commences Clinical Phase I Combination Study

Active Biotech AB has commenced enrolment for a clinical Phase I combination study of its candidate drug, ANYARA, with the cancer drug, Taxotere. The study is designed to evaluate the two drugs in combination as a treatment for non-small cell lung cancer.

This dose-escalation study, expected to include between 20 and 30 patients, will examine the response to increasing doses of ANYARA in combination with a fixed dose of Taxotere. Taxotere will be administered according to the established dosing schedule; ANYARA will be dosed at levels expected to have an anti-tumour effect.

Additionally, Active Biotech is conducting a clinical Phase I dose-escalation study of ANYARA-only that is currently ongoing in the USA, Norway and the UK.

For further information, please contact:

Sven Andréasson,

President & CEO,

Tel: +46 46 19 20 49

Email: sven.andreasson@activebiotech.com

Or visit: www.activebiotech.com